At ViiV Healthcare, our goal is simple: to end the HIV epidemic. Over the last 40 years, there have been incredible advances in the development of effective HIV treatments that allow people living with HIV to suppress their virus to undetectable levels.

However, the needs of people living with HIV change over time, and we‘re exploring new ways of treating and preventing HIV through new mechanisms of action and drug delivery.

We have a number of potential medicines in development for the treatment and prevention of HIV.

Clinical development pipeline

Product/Investigational Compound
Mechanism of action
Phase
Cabotegravir
(long acting formulation by intramuscular injection)
Integrase strand transfer inhibitor III
(for pre-exposure prophylaxis)
GSK-3640254
HIV maturation inhibitor Pre-clinical
GSK-3739937 HIV maturation inhibitor Pre-clinical
GSK-3810109 HIV attachment inhibitor Pre-clinical
GSK4023991 Nucleoside Reverse Transcriptase Translocation Inhibitor (NRTTI) Pre-clinical

RELATED TOPICS

Discover how we work with leading researchers and academic groups to innovate and bring the best science to HIV treatment, prevention and care.

With significant progress made in the fight against HIV, how do we make sure that clinically proven tools are implemented into real-world settings?